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Abstract
Background: Long-term remission of HIV-1 disease can be readily achieved by combinations of highly effective
antiretroviral therapy (HAART). However, a residual persistent immune activation caused by circulating non infectious
particles or viral proteins is observed under HAART and might contribute to an higher risk of non-AIDS pathologies and
death in HIV infected persons. A sustained immune activation supports lipid dysmetabolism and increased risk for
development of accelerated atehrosclerosis and ischemic complication in virologically suppressed HIV-infected persons
receiving HAART.
Aim: While several HIV proteins have been identified and characterized for their ability to maintain immune activation, the
role of HIV-p17, a matrix protein involved in the viral replication, is still undefined.
Results: Here, we report that exposure of macrophages to recombinant human p17 induces the expression of
proinflammatory and proatherogenic genes (MCP-1, ICAM-1, CD40, CD86 and CD36) while downregulating the expression
of nuclear receptors (FXR and PPARc) that counter-regulate the proinflammatory response and modulate lipid metabolism
in these cells. Exposure of macrophage cell lines to p17 activates a signaling pathway mediated by Rack-1/Jak-1/STAT-1 and
causes a promoter-dependent regulation of STAT-1 target genes. These effects are abrogated by sera obtained from HIV-
infected persons vaccinated with a p17 peptide. Ligands for FXR and PPARc counteract the effects of p17.
Conclusions: The results of this study show that HIV p17 highjacks a Rack-1/Jak-1/STAT-1 pathway in macrophages, and
that the activation of this pathway leads to a simultaneous dysregulation of immune and metabolic functions. The binding
of STAT-1 to specific responsive elements in the promoter of PPARc and FXR and MCP-1 shifts macrophages toward a pro-
atherogenetic phenotype characterized by high levels of expression of the scavenger receptor CD36. The present work
identifies p17 as a novel target in HIV therapy and grounds the development of anti-p17 small molecules or vaccines.
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Introduction
Matrix proteins are essential in the viral replication cycle. The
major structural protein of all retroviruses is a multidomain
polypeptide called Gag that is capable of assembling into virus-like
particles in the absence of other viral constituents [1–4]. The HIV-
1 Gag is synthesized as a precursor polyprotein, Pr55Gag, which
consists of four major domains cleaved by the virally-encoded
protease into its mature products p17 matrix, p24 capsid, p7
nucleocapsid, the carbossi (C)-terminal p6, and several small
polypeptides including p1 and p2 [1]. The HIV-1 matrix protein
p17 encompasses the amino (N)-terminal domain of the gag gene
and, in mature virions, is a 132-AA polypeptide myristoylated at
the N-terminus which forms a protective shell associated directly
with the inner leaflet of the viral membrane [1–4]. The P17 serves
several function in the viral replication cycle including viral
nuclear import at early stage of infection. In the late stage, p17
mediates the recruitment of the viral surface/transmembrane
gp120/gp41 envelope protein complex into virions and targets
Pr55Gag proteins to their assembly sites at the plasma membrane
of infected cells [1–4]. In addition to its role in viral replication,
HIV-1-infected cells release significant amounts of virion-free p17.
This exogenous p17 is detected in the plasma of HIV-1-infected
persons at nanomolar concentrations [5] and the protein might
accumulate in the germinal center of lymphonodes in HIV
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(HAART) [6–9]. P17 dysregulates biological activities of different
immune cell types that are directly or indirectly involved in AIDS
pathogenesis (i.e. T lymphocytes, monocytes and dendritic cells)
[10]. These activities occur after p17 interaction with a cell surface
receptor (p17R) which is expressed by a definite subset of immune
cells [10]. The nature of this receptor is still unknown, althought
p17 binds to heparan sulphate side chains of syndecan-2,
syndecan-4 and CD44v3 and these heparan sulphate proteogly-
cans colocalize with HIV-1 p17 on activated human CD4+ T cells
[11].
Monocytes/macrophages play an important role in HIV
infection. Thus, while less susceptible than CD4+ T lymphocytes
to viral cytopathic effects, they are resistant to HIV-1-induced
apoptosis [12] and therefore serve as a major virus reservoir [13].
The analysis of HIV-infected monocytes shows activation of
multiple signalling cascades leading to up-regulation of variety of
inflammation-related molecules that might sustain both inflam-
mation and HIV-1 replication [14,15]. Molecular dissection of the
relative contribution of p17 to this phenotype has revealed that
exposure of human monocytes, that constitutively express the
p17R, to p17 triggers the release of MCP-1 [16] a chemokine
whose regulation is achieved through the activation of the signal
transducers and activators of transcription (STAT)-1 pathway
[17], which is prominent in regulating chemokines mediated
inflammatory responses and has been implicated in the patho-
genesis of HIV infection and disease progression [18–20].
In addition to their role in immune response, monocytes exert
metabolic functions [21,22]. Reciprocal regulation of immune
metabolic activities in these cells is achieved by the activities of
member of the nuclear receptors superfamily [23–25]. Thus,
modulation of peroxisome proliferator-activated receptor (PPAR)
a and c, liver–x-receptor (LXR) a and b, farnesoid –x-receptor
(FXR), vitamin D receptor (VDR) in these cells triggers a
reciprocal regulation of immune and metabolic pathways [24–
27]. Because the activity of these nuclear receptors is anti-
inflammatory in nature, their expression is often downregulated in
monocytes undergoing immune activation [28]. In the present
study we provide evidence that the HIV-1 p17 matrix protein
shifts macrophages to a pro-inflammatory and pro-atherogenic
phenotype and that this effects is reached through the downreg-
ulation of the expression/function of PPARc and FXR. Because
these effects are achieved by the highjacking of a Rack-1/Jak-1/
STAT-1 pathway and are reversed by STAT-1 inhibition, this
study identify novel targets for the treatment of immune activation
and metabolic dysfunction in virologically suppressed HIV-
infected persons.
Results
p17 treatment regulates macrophage functions in
humans
To characterize the effect of p17 on macrophage activation,
CD14-derived peripheral blood mononuclear cells (PBMC) from
healthy donors were stimulated 18 hours with 1 mg/ml p17. As
shown in Figure 1A and B, p17 treatment caused a significant
monocytes aggregation as documented by phase-contrast micros-
copy analysis of these cells. This phenotype was in accordance
with Real-Time PCR data showing an increased expression of the
adhesion molecule ICAM-1 following p17 stimulation (Fig. 1C). In
addition, exposure to p17 caused a robust increase in the
expression of proinflammatory mediators including MCP-1 as
well as of co-stimulatory molecules such as CD80, CD86 and
CD40 (Fig. 1C and D). This inflammatory phenotype associated
with a dysregulation of the expression of genes involved in lipid
metabolism. Thus, p17 increased CD36 mRNA expression while
failed to boots ABCA1 (Figure 1E). Since macrophages activation
results in a reciprocal regulation of immune response and lipid
metabolism and this integration is reached to the activation of
members of the nuclear receptor superfamily (e.g. FXR and
PPARc) [23–27], we have investigated whether p17 stimulation
regulates the expression of these transcription factors. As shown in
Figure 1C, a slightly down-regulation of FXR and PPARc was
found in CD14-derived PBMC following stimulation with p17,
unrevealing a novel role for this viral protein in regulating lipid
metabolism and immune responses these cells.
Biological activities of p17 were almost completely
neutralized by therapeutical vaccination
Having shown that p17 protein regulates the expression of
nuclear receptors as well as that of genes involved in cell adhesion,
inflammatory response and lipid metabolism we have investigated
whether these effects could be reproduced in CD14-derived
PBMC isolated from virologically suppressed HIV infected
persons receiving HAART. For these studies CD14-derived
PBMC cells were stimulated ex vivo with 1 mg/ml p17. As shown
in Figure 2 A, B and C, p17 treatment induces monocytes
aggregation and effectively increased the expression of pro-
inflammatory genes, including MCP-1, TNFa, IL-1b and
ICAM-1 (Fig. 2B). To investigate whether these effects of p17
were receptor specific, we took advantage from the availability of
sera obtained from HIV-infected patients vaccinated with p17
peptide. These sera contain neutralizing p17 antibodies (Method
S1 and Figure S1). Of interest p17 neutralization with p17 antisera
effectively reversed the stimulatory effects of p17 on macrophages
(Fig. 2C). Indeed, exposure to anti-p17 retained in sera of the
vaccinated patients almost completely abrogate the effects of p17
in terms of induction of MCP-1, ICAM-1, CD36, CD80 and
CD40 but were not able to counter-regulates the induction of
CD86, TNFa and IL1b (Fig. 2 D, E and F). In contrast to the
effects seen in healthy donors, p17 treatment failed to down-
regulate the expression of FXR and PPARc in CD14-derived
PBMC isolated from HIV patients while p17 immune-neutraliza-
tion significantly induced the expression of these nuclear receptors,
further supporting the view that p17 is a negative regulator of
FXR and PPARc. All together these data confirmed that some of
the effects of p17 observed in CD14-derived PBMCs obtained
from healthy donors were maintained in HIV infected macro-
phages and that anti-p17 immune-neutralization leads to a specific
reversion on these activities.
p17 treatment regulates macrophage functions in THP-1
cells
The signalling pathways mediating the effects of p17 on
macrophages were investigated by using THP-1 cells, a myeloid
monocytic cell line. As expected, exposure of these cells to p17
(1 mg/ml) caused a robust increase in the expression of ICAM-1,
MCP-1, TNFa and IL1b mRNA as well as of co-stimulatory
molecules CD40, CD80 and CD86 (Fig. 3A and B). The analysis
of genes involved in lipid metabolism revealed that p17 stimulation
effectively increases CD36 but not ABCA1 mRNA. In addition,
exposure of THP1 cells to p17 caused a robust downregulation of
FXR and PPARc mRNA (Fig. 3A and C).
p17 induces STAT1 phosphorylation in THP-1 cell line
Previous studies have shown that the expression of MCP-1,
ICAM-1, CD40, CD86 and CD36 is induced in STAT-1
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results in down regulation of FXR and PPARc gene expressions
[29–31]. Because the STAT-1 pathway could be activated through
a Rack-1/Jak-1 pathway and p17 binds to syndecan-2, a
glycoprotein that effectively recruits Rack-1 to a multiprotein
complex at the cell membrane [11,32–33] we then investigated
whether exposure of THP1 cells to p17 activates this pathway
(Figure 4A). For this purpose lysates from THP-1 cells left
untreated or primed with p17 were immunoprecipitated with an
anti-Rack-1 antibody and immunoblotted with antibodies against
Syndecan-2 and Jak-1. Results from this experiment demonstrated
that p17 stimulation recruits Rack-1 into a syndecan-2/Rack-1
multiprotein complex within 5 min of exposure and that this
protein-protein complex dissociates after 15 and 30 minutes
(Figure 4B). This multiprotein complex is also characterized by
the recruitment of Jak-1, though the interaction of the later protein
with syndecan 2 and Rack-1 is maintained up to 30 minutes
(Figure 4B). The results of these experiments were consistent with
results from Western blotting analysis of the time-course of Jak-1
phosphorylation. Indeed, Jak-1 phosphorylation, a measure of Jak-
1 activation, occurs between 15 and 30 minutes exposition to p17,
but decreases thereafter (Figure 4C). Furthermore, exposure of
THP-1 cells to p17 resulted in STAT-1 phosphorylation that
became apparent after 60 min of incubation with 1 mg/ml p17.
All together, these data support the notion that p17 signals
through a pathway involving syndecan-2/RACK-1/Jak-1 and
STAT-1.
Since previous studies have demonstrated that the promoter of
MCP-1 as well as the intron-II of FXR gene are regulated in a
STAT1 dependent manner [19,30] we have then examined
whether p-17 mediated activation of STAT-1 regulates the
transcription of these genes. Thus, as illustrated in Figure 4E,
kinetic of MCP-1 promoter occupancy revealed that the binding of
STAT-1 peaked at 6 hours and was maintained until 18 hours
treatment of THP-1 cells to p17. We have repeated the ChIP and
demonstrated that, similar to the MCP-1 promoter, STAT-1 also
bound to the intron-II of FXR gene after 18 hour-stimulation with
p17.
STAT-1 inhibitor fludarabine reverses p17 effects on
macrophages
To demonstrate the relevance of STAT-1 in the context of the
regulatory activity exerted by p17 in macrophage’s cell lines, we
pretreated THP-1 cells with fludarabine, a STAT1 inhibitor [34],
before the challenge with p17. As illustrated in Figure 5A, p17
mediated STAT-1 phosphorylation was inhibited by fludarabine
co-treatment, and exposure to this agent completely reversed
regulatory effects exerted by p17 on MCP-1, ICAM-1, CD40,
CD80, CD86 and PPARc.
Figure 1. HIV-1 p17 regulates pro-inflammatory, co-stimulatory and pro-atherogenic molecules in CD14-derived PBMC isolated
from healthy donors. CD-14 derived PBMC isolated from healthy donors were stimulated for 18 hours with 1 mg/ml p17 recombinant protein. (A
and B) Exposure to p17 drives an activated phenotype in macrophages and causes macrophages adhesion. Magnification 206. (C) Relative mRNA
expression of proinflammatory cytokines TNFa, IL1b, MCP-1, ICAM-1 and nuclear receptors FXR and PPARc. (D) Relative mRNA expression of co-
stimulatory molecules CD40, CD80 and CD86. (E) Relative mRNA expression of proatherogenic genes CD36 and ABCA1. Real-Time analysis was carried
out in triplicate and the experiment was repeated twice. *P,0.05 versus not treated cells.
doi:10.1371/journal.pone.0035924.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35924Figure 2. HIV-1 p17 exerts regulatory effects on CD-14 derived PBMC isolated from HIV infected patients. CD-14 derived PBMC isolated
from HIV infected patients vaccinated with an anti-p17 vaccine were stimulated ex vivo with 1 mg/ml p17 for 18 hours with or without the serum of
the same patients (diluted 1:100 in medium culture). (A–C) Activation of CD-14 derived PBMC caused by p17 (b) was reserved by p17 immune-
neutralization with anti-p17 serum. Magnification 206. (D) Relative mRNA expression of proinflammatory cytokines TNFa, IL1b, MCP-1, ICAM-1 and
nuclear receptors FXR and PPARc. (E) Relative mRNA expression of co-stimulatory molecules CD40, CD80 and CD86. (F) Relative mRNA expression of
proatherogenic genes CD36 and ABCA1. Real-Time analysis was carried out in triplicate and the experiment was repeated twice. *P,0.05 versus not
treated cells. #P,0.05 versus p17 stimulated cells.
doi:10.1371/journal.pone.0035924.g002
Figure 3. Stimulation of THP-1 cells with p17 causes reciprocal regulation of genes involved in immune function and lipid
metabolism. THP-1 cells were stimulated with 1 mg/ml p17 recombinant protein for 18 hours. (A) Relative mRNA expression of proinflammatory
mediators TNFa, IL1b, MCP-1, ICAM-1 and nuclear receptors FXR and PPARc. (B) Relative mRNA expression of co-stimulatory molecules CD40, CD80
and CD86. (C) Relative mRNA expression of proatherogenic genes CD36 and ABCA1. Real-Time analysis was carried out in triplicate and the
experiment was repeated twice. *P,0.05 versus not treated cells.
doi:10.1371/journal.pone.0035924.g003
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biological activities of p17
Since FXR and PPARc exert their regulatory activities at the
interface between inflammation and metabolism and their
expression is negatively regulated by exposure to p17, we have
then speculated whether ligands for these transcription factors
could reverse the effects of p17. For this purpose THP-1 cells were
incubated with p17 alone or in the presence of GW-4064 or
rosiglitazone, two selective agonists for FXR and PPARc.A s
shown in Figure 6, FXR activation with GW4064 effectively
down-regulated TNFa, IL1b, ICAM-1, MCP-1,CD40 and CD80
induction caused by p17 (Figure 6A), but failed to reverse
induction of CD86 (Fig. 6B). Furthermore the FXR agonist
significantly reverted regulation of CD36 and ABCA1 mRNA
caused p17 (Figure 6C). Similarly to the FXR agonist, the PPARc
ligand rosiglitazone counteracted induction of TNFa, IL1b,
ICAM-1, MCP-1, CD40 and CD86 (Figure 7A) caused by p17
but failed to do the same on CD80 (Fig. 7B). Additionally, PPARc
activation failed to reverse the induction of CD36 mRNA caused
by p17. This was not surprising because PPARc is a well know
inducer of CD36 gene expression [35].
Discussion
Persistent immune activation and lipid dysmetabolism occur
often in virologically suppressed HIV infected persons taking
HAART and are thought to make a contribution to long-term
effects linked to chronic HIV infection [36]. Because HAART per
se might induce hypetrglyceridemia, the current view is that
concomitant effects derived from HIV infection per se and side
effects due to HAART are both causative factors for the increased
risk of accelerated atherosclerosis and ischemic cardiovascular
events in long term survival HIV-infected persons [37]. Beside the
role of HAART, however, the virus infection per se has been shown
to drive a chronic state of subclinical inflammation in successfully
treated patients. Since under HAART more than 99% of HIV-1
particles detected in the circulation are not productively infectious
Figure 4. p17 signals through RACK-1/Jak-1/STAT-1 pathway in THP-1 cells. (A) Schematic diagram showing putative interaction of p17
with syndecan-2 and the activation of RACK-1/Jak-1/STAT-1 signal transduction pathway. (B) Co-immuneprecipitation of RACK-1 with syndecan-2 and
Jak-1 following stimulation of THP-1 cells with p17 recombinant protein (1 mg/ml) for 5, 15 and 30 minutes. (C) Analysis of Jak-1 protein (total and
phosphorylated fraction) by immune blot in THP-1 cells stimulated with p17 (1 mg/ml) for 15, 30 and 60 minutes. (D) Analysis of STAT-1 protein (total
and phosphorylated fraction) by immune blot in THP-1 cells stimulated with p17 (1 mg/ml) for 15, 30 and 60 minutes. (E) Chromatin
Immunoprecipitation assay carried out in THP-1 cells left untreated or primed with 1 mg/ml p17 for 1, 6 and 18 hours. Real-Time PCR was performed
on MCP-1 promoter. (F) Chromatin Immunoprecipitation assay carried out in THP-1 cells left untreated or primed with 1 mg/ml p17 for 18 hours. Real-
Time PCR was performed on both MCP-1 promoter and intron-II of FXR gene. Values are normalized relative to input DNA concentration and are
expressed relative to those of not treated cells immunoprecipitated with an anti IgG antibody, condition set as 1. Analysis was carried out in triplicate
and the experiment was repeated twice. *P,0.05 versus not treated cells. **P,0.05 versus p17 stimulated cells.
doi:10.1371/journal.pone.0035924.g004
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make a contribute to these complications [38–42]. The p17 HIV-
matrix protein is a structural protein whose biological functions
are deemed essential for virus life cycle [4]. In addition, p17
displays a variety of biological activities outside the infected cells
[4]. Despite molecular mechanisms mediating these effects are
incompletely identified, the role of p17 in maintaining chronic
inflammation in virologically suppressed patients should not be
minor, because the presence of anti-p17 neutralizing antibodies in
the plasma of HIV infected patients correlates with a better
prognosis and slows the disease progression [43].
Confirming a common theme in chronic infection (i.e. the
ability of viral proteins to pirate molecular targets in mammalian
cells) the HIV p17 has been shown to interact with putative
binding sites on activated CD4+ and CD8+ T cells as well as on
NK cells [10–11]. Despite the nature of this p17R is still under
investigation, exposure to p17 triggers a complex system of second
messengers and leads to an activated phenotype of immune cells
[44].
Figure 5. An intact STAT-1 signal is required to mediate the biological activity of p17. THP-1 cells were stimulated for 18 hours with p17
(1 mg/ml) in presence or in absence of a specific STAT-1 inhibitor fludarabine (0.5 mM). At the end of treatments cellular lysates were used for Real-
Time or immunoblot analysis. (A) Immunoblot of STAT-1 protein (total and phosphorylated fraction). (B) Relative mRNA expression of MCP-1, ICAM-1,
PPARc, CD40, CD80 and CD86 was expressed relative to not treated cells. Analysis was carried out in triplicate and the experiment was repeated
twice. *P,0.05 versus not treated cells. #P,0.05 versus p17 stimulated cells.
doi:10.1371/journal.pone.0035924.g005
Figure 6. FXR agonist, GW-4064, reverses the effects exerted by p17 on THP-1 cells. THP-1 cells were pre-incubated 2 hours with GW-4064
(1 mM) before administration of p17 (1 mg/ml for 18 hours). Total RNA was extracted and the relative mRNA expression of (A) proinflammatory
cytokines and nuclear receptors, (B) co-stimulatory molecules and (C) proatherogenic genes was assayed by Real-Time PCR. Values are expressed
relative to not treated cells. Analysis was carried out in triplicate and the experiment was repeated twice. *P,0.05 versus not treated cells. **P,0.05
versus p17 stimulated cells.
doi:10.1371/journal.pone.0035924.g006
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regulatory function on macrophages by simultaneously interaction
with immune and metabolic activities of these cells. Because
macrophages exert an essential role in both innate immunity and
lipid metabolism and lipid-engulfed macrophages (foam cells) are
prototypical to atherosclerotic plaques [45], our data establish a
robust link between the modulation of these cells and lipid
dysmetabolism observed in HIV infected persons. Despite the cell
surface receptor of p17 in macrophages was not defined in the
present study, we have provided robust evidence that such a target
does exist. Indeed, taking advantage of sera obtained from HIV
infected persons enrolled in a phase I trial testing the safety of an
anti-p17 vaccine, we have found that immune neutralization of
p17 with sera of these patients completely reverts the regulatory
functions of the recombinant protein in macrophages.
While numerous studies have investigated the role of anti-HIV
drugs in lipodystrophy and dyslipidemia [37], the effects of HIV
infection on cellular cholesterol metabolism remain poorly
characterized. Recently, a role for the CD36 scavenger receptor
as well as for the ATP-binding cassette transporter A1 (ABCA1) in
the genesis of HIV-related dyslipidemia has been propsed [46,47].
In macrophages CD36 mediates the uptake of oxidized low-
density lipoproteins (ox-LDLs). Thus, the expression of CD36 is
essential to cholesterol accumulation in these cells, their transition
to foam cells and development of atherosclerotic lesions [48].
Conversely, the protein transporter ABCA1 is involved in
cholesterol efflux from macrophages [49]. Results presented here
demonstrated that the HIV-1 matrix protein p17 regulates the
expression of these genes in macrophages isolated from healthy
donors and HIV-infected persons treated with HAART, despite
the magnitude of the reported effects was different. In these cells,
p17 significantly induces CD36 mRNA expression but fails to alter
the levels of ABCA1, thought that a minor increase in the
expression of this gene was observed in THP1 cells. These data are
consistent with previous works showing increased levels of
circulating CD36 while the levels of ABCA1 are reduced or
unchanged in HIV infected persons under HAART, and support
the notion that HIV infection resets the expression of genes to a
pattern that favours the accumulation of intracellular lipids
[46,47].
In the present study we provided evidence that exposure of
macrophages to recombinant p17 effectively increases the
expression of ICAM-1 mRNA. Several studies have demonstrated
that circulating levels of ICAM-1 are increased in HIV-infected
and acquired immune deficiency syndrome (AIDS) persons [50].
Despite regulatory cytokines such as TNFa and IL1b may
contribute to the increased levels of ICAM-1 [51] we have now
made the important observation that HIV matrix protein p17
contributes to the induction of this pro-inflammatory mediator.
Because the role of viral proteins in resetting the immune system in
HIV infection is not completely understood, we have investigated
whether p17 regulates the expression/generation of prototypical
cytokines in PBMC isolated from healthy subjects and HIV
infected persons. Our results demonstrated that exposure of
macrophages to this protein effectively increases the expression of
TNFa and IL1b mRNA in macrophages isolated from HIV
infected patients but not in healthy donors macrophages,
suggesting that p17 signals as ‘‘co-stimulatory’’ molecule in this
settings.
Adding to the immune-regulatory role of p17 in macrophages
we provided evidence that p17 significantly increases the
expression of CD40 mRNA. CD40 is a cell-surface co-stimulatory
molecule involved in macrophage activation by its ligation via
CD154 (CD40L) expressed on activated CD4+ T cells [52].
Ligation of CD40, drives the synthesis of pro-inflammatory
cytokines including TNFa and IL1b as well as of other co-
stimulatory molecules including CD80 and CD86 [52]. Consistent
with the ability of p17 to reset the expression of CD40 we also
observed an up-regulation of CD80 and CD86 in macrophages
exposed to p17. These observations might have a translation
readout since a growing body of evidences supports a role for the
CD40 pathway in macrophage activation as well as in the
atherosclerosis progression [53].
Another important observation we made in this study was the
demonstration that p17 causes a robust decrease in the expression
of two nuclear receptors, FXR and PPARc, in THP1, while this
Figure 7. The PPARc agonist, rosiglitazone, differentially regulates p17 biological activities. THP-1 cells were pre-incubated 2 hours with
rosiglitazone (1 mM) before administration of p17 recombinant protein (1 mg/ml for 18 hours). Total RNA was extracted and the relative mRNA
expression of (A) proinflammatory cytokines and nuclear receptors, (B) co-stimulatory molecules and (C) proatherogenic genes was analyzed by Real-
Time PCR. Values are expressed relative to not treated cells. Analysis was carried out in triplicate and the experiment was repeated twice. *P,0.05
versus not treated cells. **P,0.05 versus p17 stimulated cells.
doi:10.1371/journal.pone.0035924.g007
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HIV infected persons, and macrophages from healthy subjects
showed an intermediate phenotype. FXR and PPARc are
transcription factors that play a role in the regulation of lipid
metabolism and immune function in monocytic cells [24–26].
Their regulatory activity is inhibitory in nature and therefore both
receptors have been proposed as potential candidates to take
control over dysregulated immune response and lipid metabolism
in the setting of chronic inflammatory disorders-associated
metabolic dysfunctions [27]. We have now provided evidence
that an HIV viral protein has the potential to modulate the
expression of these nuclear receptors and that abrogation of the
expression of FXR and PPARc is instrumental to the development
of proinflammatory activity of p17 in macrophages. Support to
this view comes from the observation that exposure of p17 treated
macrophages to FXR and PPARc ligands reverts the immune
activated phenotype and counter-regulates the expression of
metabolic genes. However, it has to be noted that the effects
exerted by the FXR and PPARc agonists differ under some
aspects. Thus, while GW4064 effectively reduced p17-mediated
CD40 and CD80 co-stimulatory molecules expression, it failed to
reverse the induction of CD86. In contrast, rosiglitazone reduced
p17-medaied CD40 and CD86 expression, but failed to reverse
the induction of CD80 mRNA. Because the two ligands act on
different targets these discrepancies are likely linked to their
specific mode of action [24–27].
In the present study we have also investigated whether a
common motif could support the regulatory effects p17 exerts on
immune and metabolic functions in macrophages. Intracellular
dissection of these signaling pathways took advantage from the
demonstration that physical interaction between p17 and
syndecan-2 at plasma membrane supports the activation of human
CD4+ T cells exposed to the matrix protein [11]. Previous studies
have shown that syndecan-2 interacts with Rack-1 [32] while
phosphorylated Rack-1 is recruited in a protein complex with Jak-
1 [33]. Consistent with this hypothesis, exposure to p17 causes the
formation of a multiprotein complex containing syndecan-2,
Rack-1 and Jak-1. In addition, we provided evidence that
activated Jak-1 phosphorylates and activates STAT-1. Because
STAT-1 is recruited to specific STAT-1 binding sites in the
promoter regions of MCP-1, FXR and PPARc our data provided
a robust evidence that by pirating a Rack-1/Jak-1/STAT-1
pathway the HIV protein p17 takes control over immune and
metabolic functions in macrophages. This view was further
confirmed using fludarabine, a pharmacological inhibitor of
STAT-1. Of relevance, fludarabine almost completely reversed
the biological activities of p17 on macrophages.
In summary, findings presented in this study demonstrated that
the HIV-1 matrix protein p17 interferes with intracellular lipid
metabolism and immune function in macrophages. This study
highlights the potential use of FXR and PPARc agonists as well as
of the therapeutic p17 vaccine or small molecule inhibitors as
potential agents for the treatment of immune and metabolic
dysfunction in HIV infection.
Materials and Methods
Patients
To investigate whether p17 neutralization effectively antago-
nizes the effects exerted by p17 on human macrophages, p17 was
immune-neutralized by incubation with sera from HIV infected
persons enrolled in a Phase 1 study designed to investigate the
safety and immunogenicity of recombinant p17 peptide in HIV.
The therapeutic vaccination was performed using a 20 amino
acids peptide, named AT20 (SGGELDRWEKIRLRPGGKKK).
Previous studies have shown that immunization of animals with
AT20 resulted in the development of p17 neutralizing antibodies
capable of blocking all biological activities of the viral protein [54].
The vaccination protocol n. MED-AT20-001 Eudract Number
2008-001465-29 was approved by the Ethical committee of
Regione Umbria (Italy) on June 25, 2010 authorization n. 1558/
10. Authorization for collecting and using blood samples from HIV
infected persons for ex vivo testing was also granted by the ethical
committee of Regione Umbria (Italy) on July 22, 2010 (authoriza-
tion number CEAS 1654/20). An informed written consent was
obtained from each participant to the study. At the end of the study
blood samples were obtained from three patients and the
recombinant p17 protein was immune-neutralized by pre-incuba-
tion with the serum of these patients. The presence of anti-p17
antibodies in the blood of these subjects was verified by micro-Elisa.
Reagents
HIV-p17 recombinant protein was provided by Medestea
(Torino, Italy). The FXR ligand GW-4064, the PPARc ligand
rosiglitazone and the specific STAT-1 inhibitor fludarabine were
from Sigma Aldrich.
Isolation and culture of human CD14-derived PBMC
PBMC were first isolated by density gradient centrifugation
using the Hystopaque reagent (Pharmacia Biotech) and then
positively selected using CD14 magnetic beads and LS columns
according to the manufacturer’s instructions (Miltenyi Biotec).
After isolation cells were stimulated 18 hours with 1 mg/ml p17 in
RPM-I supplemented with 10% Fetal Bovine serum, 1% L-
glutamine and 1% penicillin/streptomycin. PBMC isolated from
vaccinated HIV patients were also stimulated with the combina-
tion of p17 (1 mg/ml) and serum (diluted 1:100 in culture
medium).
Microscopic images acquisition
Images of PBMC were acquired with a Nikon Eclipse TE300
microscope using a Nikon Digital Camera DXM1200.
Cell culture
THP-1 cells, a human acute monocytic leukemia cell line
(ATCC collection imported by Promochem, Milan, Italy), were
cultured in RPM-I medium supplemented with 10% Fetal Bovine
serum, 1% L-glutamine and 1% penicillin/streptomycin.
Real-Time PCR
Total RNA was isolated from livers of cells using the TRIzol
reagent (Invitrogen). RNA (1 mg) was reverse-transcribed using
random hexamer primers and Super Script II reverse transcriptase
(Invitrogen). mRNA were quantified by Real-Time quantitavive
PCR on iCycler apparatus (Biorad) using specific primers:
hGAPDH: gaaggtgaaggtcggagt and catgggtggaatcatattggaa; hFXR:
tacatgcgaagaaagtgtcaaga and actgtcttcattcacggtctgat; hPPARc:
gctggcctccttgatgaata and ttgggctccataaagtcacc; hMCP1: ccccagt-
cacctgctgttat and tcctgaacccacttctgctt; hICAM1: agcttctcctgctctg-
caac and cattggagtctgctgggaat; hIL1b: ggacaagctgaggaagatgc and
tcgttatcccatgtgtcgaa; hTNFa: aacctcctctctgccatcaa and ggaagac-
ccctcccagatag; CD40: ctcagaaacagacaccatctgc and tcagaaacccctg-
tagcaatct; CD80: agggaacatcaccatccaag and tgccagtagatgcgagtttg;
CD86: agacgcggcttttatcttca and ccctctccattgtgttggtt; ABCA1: gctt-
gggaagatttatgacagg and aggggatgattgaaagcagtaa; CD36: tttctgtatg-
caagtcctgat and attaagccaaagaataggcac. PCR amplifications and
data analysis were performed as described [55].
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6 THP-1 cells serum starved over-night were stimulated
with p17 (1 mg/ml) for 15, 30 and 60 minutes. To investigate the
effects of Fludarabine (a specific STAT-1 inhibitor) THP-1 cells,
serum starved over night, were stimulated with p17 (1 mg/ml)
alone or in combination with Fludarabine (0.5 mM) for 18 hours.
Total lysates were prepared by solubilization of cells in E1A lysis
buffer containing phosphatase and protease inhibitors. Proteins
were separated by polyacrylamide gel electrophoresis, transferred
to nitrocellulose membranes (Bio-Rad) and probed with primary
antibodies, phosphoSTAT1(Tyr701) (Cell Signaling - #9171),
STAT1 (Cell Signaling - #9172), phospho-Jak-1 (Santa Cruz – sc-
101716) and Jak-1 (Santa Cruz – sc-7228). The anti-immuno-
globulin G horseradish peroxidase conjugate (Bio-Rad) was used
as the secondary antibody, and specific protein bands were
visualized using the Luminata Forte Western HRP substrate
(Millipore) following the manufacturer’s suggested protocol.
Immunoprecipitation
To decipher the p17 intracellular signalling THP-1 cells were
serum starved over-night and then stimulated with p17 (1 mg/ml)
for 15, 30 and 60 minutes. After the stimulation, cells were washed
3 times with ice-cold PBS and lysed with an insulin syringe in
500 ml E1A lysis buffer (250 mM NaCl, 50 mM Hepes pH 7.0,
0.1% NP40, 5 mM EDTA). Lysates were incubated 20 minutes in
ice, clarified by centrifugation at 12000 rpm for 20 minutes at 4uC
and quantified with Bradford reagent (PIERCE). 200 mg total
proteins were pre-cleared on a rotating wheel for 1 h at 4uC using
protein A Sepharose beads (Amersham Biosciences) and 2 mgo f
irrelevant antibody of the same species and isotype as RACK-1
(IgG2a (7D5) antibody (Santa Cruz - sc-69917)). Immunoprecip-
itation was performed overnight at 4uC with 1 mg RACK-1
antibody (Santa Cruz – sc-17754) or IgG as a negative control
antibody in the presence of 40 ml of protein A Sepharose
(Amersham Biosciences). The resultant immunoprecipitates were
washed five times with 1 ml of lysis buffer and then used for
western blotting using the antibodies syndecan-2 (Santa Cruz – sc-
365624), Jak-1 and RACK-1.
Chromatin Immunoprecipitation (ChIP)
THP1 cells serum starved over-night were stimulated for 1, 6
and 18 hours with p17 (1 mg/ml) were cross-linked with 1%
formaldehyde at room temperature and the reaction was
terminated by the addition of glycine to a final concentration of
0.125 M. Cells were washed in ice-cold PBS and lysed with SDS
lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris–HCl,
pH 8). Cellular lysates were diluted with ChIP dilution buffer,
sonicated, and immunoprecipitated with specific antibody anti-
STAT-1 (Cell Signaling - #9172). Immunoprecipitates were
collected with protein A beads (Amersham Bioscience) and washed
sequentially first with a low-salt wash buffer and then with high-
salt wash buffer using manufacturer’s recommended procedures.
DNA was eluted by addition of 1% SDS and 0.1 M NaHCO3,
and the cross-linking reactions were reversed by heating the
mixture to 65uC overnight. The DNA was recovered from
immunoprecipitated material by proteinase K treatment at 65uC
for 1 h followed by phenol/chloroform (1:1) extraction, ethanol
precipitation and dissolved into 50 ml of water. Five microliters of
the extract was used for quantitative real-time PCR. Raw data
analysis was performed as follows: DCt was calculated versus the
input DNA concentration; DDCt was versus unstimulated cells
immunoprecipitated with the anti-IgG antibody (experimental
condition set as 1); the relative expression was calculated as
22(DDCt).The sequences of primers used for the amplification of
the MCP1 promoter [56] and the genomic region of FXR [30]
containing a STAT-1 responsive element were: MCP1: cccatttgct-
catttggtct and cttattgaaagcgggcagag; FXR genomic: catgaccaagg-
tagatcatgac and cccaagatacgtgcttgcat.
Statistical analysis
All values are expressed as the mean 6 SE of n observations per
group. Comparisons of more than 2 groups were made with a one-
way analysis of variance with post-hoc Tukey’s tests. Differences
were considered statistically significant if p was ,0.05.
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